DOXYVA

DOXYVA sells a single flagship line of trans-dermal micro-circulation devices that deliver ultra-purified medical-grade carbon dioxide through a patented fingertip or thumb chamber. The system is positioned in the premium price tier, with starter kits and monthly refill cartridges sold direct-to-consumer through the brand’s own website and select telehealth platforms; no retail stores carry the product. The brand’s core differentiator is its clinically validated ability to raise skin and blood perfusion levels in under five minutes, a claim supported by peer-reviewed studies and FDA Class I registration. DOXYVA markets itself as a non-invasive wellness technology that supports vascular health, athletic recovery, diabetic wound care, and skin rejuvenation in one portable device. Primary buyers are health-conscious adults 35-65 managing diabetes, hypertension, or chronic pain, together with athletes seeking faster recovery and biohackers tracking perfusion metrics. The customer base values data-driven, drug-free solutions and is willing to pay for medical-grade technology that can be used at home without prescription. DOXYVA competes in the crowded wearable recovery and circulatory-health space against compression boots, infrared sleeves, and low-level light therapy pads. It separates itself by offering a glove-sized, five-minute protocol that directly increases micro-vascular blood flow rather than merely masking symptoms, and by publishing third-party clinical data that link its CO2 delivery to measurable improvements in endothelial function and wound closure rates.